Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be safe or effective.
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Eli Lilly (LLY) has reportedly sent out cease-and-desist letters to compounding pharmacies and clinics that were providing copycat versions of its drugs Zepbound and Mounjaro.
As that figure was large, weight loss drug producer Eli Lilly (NYSE: LLY) saw a nearly 2% bump in its share price in response ...
Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...
1don MSN
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback